Alzheimer's disease (AD) presently affects over 5 million Americans and is projected to affect 15 million by 2050. Biomarkers are presently the only feasible approach for diagnosing and quantifying disease-associated changes in the latent AD stage during which a successful disease-modifying therapeutic intervention would realize the greatest impact. High-throughput neuroimaging and genetics have a proven track record for critically advancing our understanding of disease mechanisms and promoting therapeutic development. Our goals are to develop a multimodal biomarker AD risk assessment tool using the prospectively collected imaging, genetic and gene expression ImaGene data set. We propose to apply advanced imaging genetics statistical approaches to achieve the following three aims: 1) identify a discovery set of AD-relevant candidate imaging and genetic biomarkers;2) select gene expression variables with strong evidence for biological relevance to AD;and 3) develop and validate a multimodal classifier capable of accurately assessing one's risk for future conversion to AD. The discovery of critical disease-related pathways will fundamentally advance our understanding of the molecular and genetic triggers of AD and bring us closer to genomic-based interventions and personalized risk assessment.
The proposed research is relevant to public health as there is an urgent need for biomarkers capable of early and presymptomatic diagnosis and for discovery of critical disease-associated pathways. The proposed research is highly relevant to the mission of NIA because it will 1) identify and test key imaging and peripheral blood genetic biomarkers that when combined will help diagnose early AD and 2) critically inform AD drug development.
|Ramirez, Leslie M; Goukasian, Naira; Porat, Shai et al. (2016) Common variants in ABCA7 and MS4A6A are associated with cortical and hippocampal atrophy. Neurobiol Aging 39:82-9|
|Clark, David Glenn; McLaughlin, Paula M; Woo, Ellen et al. (2016) Novel verbal fluency scores and structural brain imaging for prediction of cognitive outcome in mild cognitive impairment. Alzheimers Dement (Amst) 2:113-22|
|Porat, Shai; Goukasian, Naira; Hwang, Kristy S et al. (2016) Dance Experience and Associations with Cortical Gray Matter Thickness in the Aging Population. Dement Geriatr Cogn Dis Extra 6:508-517|
|Rattanabannakit, Chatchawan; Risacher, Shannon L; Gao, Sujuan et al. (2016) The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests. J Alzheimers Dis 51:1145-55|
|Apostolova, Liana G (2016) Alzheimer Disease. Continuum (Minneap Minn) 22:419-34|
|Chow, N; Hwang, K S; Hurtz, S et al. (2015) Comparing 3T and 1.5T MRI for mapping hippocampal atrophy in the Alzheimer's Disease Neuroimaging Initiative. AJNR Am J Neuroradiol 36:653-60|
|Teng, Edmond; Chow, Nicole; Hwang, Kristy S et al. (2015) Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort. Dement Geriatr Cogn Disord 39:154-66|
|Apostolova, Liana G; Hwang, Kristy S; Avila, David et al. (2015) Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology 84:729-37|
|Hwang, Kristy S; Lazaris, Andreas S; Eastman, Jennifer A et al. (2015) Plasma BDNF levels associate with Pittsburgh compound B binding in the brain. Alzheimers Dement (Amst) 1:187-193|
|Apostolova, Liana G; Zarow, Chris; Biado, Kristina et al. (2015) Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol. Alzheimers Dement 11:139-50|
Showing the most recent 10 out of 32 publications